Abstract 4945
Background
Cancer of unknown primary origin (CUP) represents a metastatic cancer with unidentified primary origin. An efficient cancer treatment algorithm is based on detection and characterization of the tumor’s origin. CUP is characterized by chromosomal instability; therefore the detection of chromosomal aberrations might contribute in tumor characterization. aCGH combines DNA microarray with CGH providing better detection rates than conventional cytogenetic methods. The present study aimed to evaluate aCGH as a technique for detection the origin of tumor, based on liquid biopsy and particular in circulating tumor cells.
Methods
Blood samples were collected from five patients suffering from prostate (2), lung (2) and breast (1) cancer and five healthy individuals. CTCs isolated using enrichment protocols while CD45 (-ve) cells isolated from healthy individuals. In addition to patients’ samples, six commercial cancer cell lines provided by ECACC were used, representing prostate and lung cancer (DU145, 22Rv1, LNcaP, COLO699N, COR0L 105 and MOR). Genomic DNA extracted and aCGH experiments followed with Sureprint G3 platform (Agilent). The genes located in chromosomal aberrations were literately analyzed and potential cancer type suggested by another researcher. The researcher performed the analysis based only on aCGH raw data, ignoring the identity and medical history of all samples. Samples firstly analyzed based on normal vs cancer prediction and secondly whether the predicted type of cancer was correct.
Results
The sensitivity was around 90% while the specificity was 80%. Among eleven cancer samples only one predicted as normal, as well as one normal sample predicted as cancer. As far as the cancer type prediction the positive predictive value was 90.1%. Only one sample categorized wrongly in total cancer samples.
Conclusions
aCGH is a powerful technique with potential of discrimination of cancer and healthy samples, but most important with ability to distinguish the type of cancer. The identification of primary origin of cancer is very important in CUP, since it is correlated with more efficient treatment algorithm. The above encouraging data from the combination of aCGH and liquid biopsy need to be validated in more samples and types of cancer so to be used at clinical level.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Research Genetic Cancer Centre S.A.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5760 - Landscape of PD-L1 expression status in Chinese solid tumor patients.
Presenter: Yi Zhong
Session: Poster Display session 3
Resources:
Abstract
3733 - Anti-cancer and immunomodulatory effects of cobimetinib in triple negative breast cancer
Presenter: Chun-Yu Liu
Session: Poster Display session 3
Resources:
Abstract
4426 - Differential expression of immunoregulatory molecules and highly-associated cancer genes may provide novel insights into strategic trial design for therapeutics
Presenter: Jacob Adashek
Session: Poster Display session 3
Resources:
Abstract
2752 - Insights into the Tumor Immune Microenvironment using Tissue Phenomics to Drive Cancer Immunotherapy
Presenter: Martin Groher
Session: Poster Display session 3
Resources:
Abstract
5713 - Immune competent somatic mosaic model of colorectal cancer
Presenter: Stefania Napolitano
Session: Poster Display session 3
Resources:
Abstract
1898 - Genomic correlates of response to anti-PDL1 Atezolizumab in non-small-cell lung cancer OAK and POPLAR trials
Presenter: Hari Singhal
Session: Poster Display session 3
Resources:
Abstract
3246 - Erdafitinib (erda) versus available therapies in advanced urothelial cancer: A matching adjusted indirect comparison
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
3311 - High level of activity of Nivolumab anti-PD-1 immunotherapy and favorable outcome in metastatic/refractory MSI-H non-colorectal cancer: Results of the MSI cohort from the French AcSé program
Presenter: Christophe Tournigand
Session: Poster Display session 3
Resources:
Abstract
2314 - TP53 and ATM Co-mutation Predicts Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Presenter: Yu Chen
Session: Poster Display session 3
Resources:
Abstract
4692 - Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients
Presenter: Raquel Laza-Briviesca
Session: Poster Display session 3
Resources:
Abstract